CD19 and lung adenocarcinoma: Increased expression levels of BLK [42] and MS4A1 [43] have been reported in lung adenocarcinoma, and BLK and CD19 [44] have been reported to be significantly correlated with the overall survival in patients with lung adenocarcinoma.